Although cytokine support can enhance CAR T-cell function, coadministering cytokines or
engineering CAR T cells to secrete cytokines can result in toxicities. To mitigate these safety …

The magnitude of CAR T cell expansion has been associated with clinical efficacy. Although
cytokines can augment CAR T cell proliferation, systemically administered cytokines can …

Although adoptive transfer of chimeric antigen receptor (CAR)-engineered T cells has
achieved unprecedented response rates in patients with certain hematological …

Despite the success of CAR-T cell cancer immunotherapy, challenges in efficacy and safety
remain. Investigators have begun to enhance CAR-T cells with the expression of accessory …

A central role for T cells in the control of cancer has been supported by both animal models
and clinical observations. Accordingly, the development of potent anti-tumor T cell immunity …

Chimaeric antigen receptor (CAR) T-cells are T-cells that have been genetically modified to
express an artificial construct consisting of a synthetic T-cell receptor (TCR) targeted to a …

Use of chimeric antigen receptors (CARs) as the basis of targeted adoptive T cell therapies
has enabled dramatic efficacy against multiple hematopoietic malignancies, but potency …

Genetically modified T cells expressing chimeric antigen receptors (CARs) so far have
mostly failed in the treatment of solid tumors owing to a number of limitations, including an …

Chimeric antigen receptor (CAR)-engineered T cells can be highly effective in the treatment
of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus …

Highlights•CAR-T cells face a battery of suppressive barriers in the solid tumor
microenvironment.•Safety, efficacy and specificity can be engineered directly into CAR …